Treatment of BRAF V600E Mutated and HER2-amplified Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality and the fourth most frequently diagnosed malignancy in the United States.1,2 It is estimated that nearly 150,000 new cases will be diagnosed in one year.1 Approximately 25% of patients with CRC are diagnosed with metastatic disease (mCRC).1-3 Colorectal tumors are highly heterogeneous and biomarker testing can be utilized to predict response to targeted therapies.3-8 Human epidermal growth factor receptor 2 (HER2) amplification or overexpression has been identified in approximately 3% of CRC cases, and nearly 10% of cases are characterized by a mutation in the BRAF gene (V600E).2-8 Though rare, these mutations comprise two distinct subtypes of mCRC and can confer a worse prognosis compared to patients with HER2-negative or BRAF wild-type tumors.2-8 In this presentation, we will discuss the relevant literature and guideline updates for treating adults with HER2-positive and BRAF V600E mutated mCRC.                                                     Speaker: Makenna Smack, PharmD, BCOP, MD Anderson

                                                                                                                                                                                                                                                                                  Be the MONARCH of your own DESTINY: Recent Updates in Breast Cancer
Breast cancer treatment is an evolving at a rapid pace.  A wide variety of HER2-directed regimens have been added to guidelines as potential treatment options for later-line HER2+, metastatic breast cancer, including fam-trastuzumab deruxtecan-nxki.  Originally approved for third-line treatment in this setting, DESTINY-Breast03 now calls into question the use of this therapy in the 2nd line setting.  Additionally, abemaciclib became the first cyclin-dependent kinase inhibitor approved in the adjuvant setting for patients with hormone-receptor positive, HER2- breast cancer.  The session will cover changes in the treatment landscape of breast cancer and what information clinicians should know when treating patients with these conditions.

Speaker: Alison Palumbo, PharmD, MPH, BCOP, Oregon State University College of Pharmacy